Amarna Therapeutics

About:

Amarna Therapeutics is a privately held European biotechnology company.

Website: http://amarnatherapeutics.com/

Top Investors: C4 Ventures, Netherlands Enterprise Agency, Eurostars, Flerie Invest, Pim Berger

Description:

Based on its unique properties SVac is ideally suited for developing next generation effective gene and immune-therapies. In order to realize our ambition to become the leading global gene therapy company they formed a worldwide consortium of key players in the virology, vector production, immunology, ophthalmology, oncology, neurology and gene therapy fields of research. With major regulatory, legal and intellectual property firms, they are developing a range of innovative and effective interventions for genetic disorders, degenerative diseases, allergies and cancer. Interventions that will dramatically improve patients’ life expectancy and quality and moreover will significantly reduce the health care costs of the society in general.

Total Funding Amount:

15M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Leiden, Zuid-Holland, The Netherlands

Founded Date:

2008-01-01

Contact Email:

info(AT)amarnatherapeutics.com

Founders:

Ben van Leent, Peter de Haan

Number of Employees:

11-50

Last Funding Date:

2022-01-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai